Clinical case: a patient has only mismatched donors. Whioch one should we choose. We discussed these issues of HLA matching, GvH and HvG diirection, the importance of differtent HLA mismatches,  premissive mismatches vs low expression alleles. Three sceanrios were discussed in detail Lecturer: Prof. Spyridonidis Participants: all...

Clinical case: PAtient wilt ALL seeks consulation for transplant or not. What is the value of MRD diagnostic? How do we perform MRD diagnostic Discussion: We discussed the challenges of MRD. The new nomenclature names MRD not minimal residula disease but measurable residual disease. Howerver...

During the last years we used different sytems to evaluate and grade chronic GvHD, which were implenmeted in our Unit. Starting form the classical limited/extensive categorization, we used the last years the NIH mild/severe/moderate classification. We dicussed a nce review form Lee regarding cGvHD...

Our previous evaluation, publisehd in BMT revealed the higher GvHD and TRM in mismatched PBSCT. We discussed our prospective study adding either MMF or 1 day post-Cy in our current 20mg Camoth anti GvHD practice.We also discussed the paper "Prospective study of nonmyeloablative, HLA-mismatched...

We discussed the QM sytem in our BMT Unit. Points that were discussed: SOP, Policies, Forms, document managment system, Corrective actions, deviations. Master files in the process from referal of a patient to transplantation and than follow up. Lecturer: Spyridonidis Participants: medical and administrative staff  

Clinical Case in our Unit: PAtient with relapsed Hodgkin with intial mediastinal involvement, now after autologous PBSCT: Should we perform consolidated radiotherapy Disucssed: the value of radiotherapy in Hodgkin, current guideleines lecturer: Prof KArdamakis, Head of the Radiotherapy dept, University of Patras Participants: all medical staff 

Clinical case in our Unit: ADV lung infection We discussed the diagnostic challenges of ADV infection and the antiviral treatment in immunocomprimised patients. Other sites of manifestation besides lung (CNS?). The value of stool diagnostics. Lecturer: M Marangos Participants: all medical staff

Bone Marrow Transplantation (2012) 47, 1499 -- 1506

BLOOD, 8 DECEMBER 2016 x VOLUME 128, NUMBER 23

From Renal Complications of Hematopoietic-Cell Transplantation Sangeeta Hingorani, M.D., M.P.H. N Engl J Med 2016; 374:2256-2267June 9, 2016DOI: 10.1056/NEJMra1404711  

N Engl J Med 2014;371:1507-17.

N Engl J Med 2015;373:599-609.

Attached is the link of the presentations of the 10 ISHL (passoword needed). The meeting was attended form 1300 participants from 70 countries.

A paper describing how to silence endogenous genes. For translational purposes on can envision to produce b2M null lymphocytes which will be universallly transplantable